FAVIPIRAVIR IN THE TREATMENT OF MILD CORONAVIRUS INFECTION: RESULTS OF A MULTICENTER OPEN-LABEL, POST-REGISTRATION, NON-INTERVENTIONAL STUDY.
Eksperimental'naya i Klinicheskaya Farmakologiya
; 86(2):18-27, 2023.
Article
in Russian
| EMBASE | ID: covidwho-2312974
ABSTRACT
Clinical parameters characterizing the efficacy and safety of favipiravir were examined in a multicenter, non-interventional (before-and-after study design) trial in 264 patients with mild COVID-19. It is shown that on the background of 14-day therapy with favipiravir body temperature normalized, blood oxygen saturation improved, and the frequency of tachycardia detection reduced by 16% (p < 0.0001). A statistically significant decrease by 91,3% (p 0.0001) in the frequency of SARS-nCoV-2 RNA detection in the nasopharyngeal mucosa discharge was revealed. A decrease in the concentration of ferritin (by 69% compared to initial values), blood glucose (by 21%), creatinine (by 10%), C-reactive protein (by 36%) (p 0.0001), and D-dimer by 61% (p = 0.016) was noted. The results of the SF-36 health survey questionnaire revealed a significant (p 0.05) improvement in the quality of life in terms of physical functioning (by 35%), and role functioning associated with physical and emotional state by 107% and 160%, respectively. Analysis of the COV19-QoL questionnaire revealed a decrease by 24% in negative perception of the disease (p < 0,01). Among the identified adverse events, elevated level of ALT (in 39.47% of patients), hyperuricemia (in 28.95% of patients), and elevated AST (in 23.68% of patients) prevailed. All the adverse events occurred with mild or moderate severity. There were no lethal outcomes in the studied sample of patients. The analysis showed a satisfactory level of the tolerability of the treatment.Copyright © 2023 Izdatel'stvo Meditsina. All rights reserved.
covid-19; efficacy; favipiravir; safety; alanine aminotransferase blood level; antiviral therapy; article; aspartate aminotransferase blood level; blood oxygen tension; body temperature; coronavirus disease 2019/dt [Drug Therapy]; disease severity; drug efficacy; drug safety; drug tolerability; emotion; ferritin blood level; glucose blood level; hospital discharge; human; hyperuricemia/si [Side Effect]; major clinical study; mucosa; multicenter study; nasopharynx; open study; protein blood level; quality of life; questionnaire; Short Form 36; side effect/si [Side Effect]; tachycardia; alanine aminotransferase/ec [Endogenous Compound]; aspartate aminotransferase/ec [Endogenous Compound]; C reactive protein/ec [Endogenous Compound]; creatinine/ec [Endogenous Compound]; D dimer/ec [Endogenous Compound]; favipiravir/ae [Adverse Drug Reaction]; favipiravir/dt [Drug Therapy]; ferritin/ec [Endogenous Compound]; glucose/ec [Endogenous Compound]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Experimental Studies
Language:
Russian
Journal:
Eksperimental'naya i Klinicheskaya Farmakologiya
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS